Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
← catalyst calendarSponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
98estimated
Sites
23
Countries
France, Germany, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-28 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Soft Tissue Sarcoma
Interventions
- Drug: Dacarbazine — also filed as DTIC
- Drug: onfekafusp alfa — also filed as L19TNF
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured The PFS rate will be assessed at 3 months.
Progression-free survival (PFS)
measured The PFS rate will be assessed at 6 months.
Progression-free survival (PFS)
measured The PFS rate will be assessed at 9 months.
Progression-free survival (PFS)
measured The PFS rate will be assessed at 12 months.
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed